Literature DB >> 28900780

Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?

Kadri Altundag1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28900780     DOI： 10.1007/s11060-017-2623-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  3 in total

1.  Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

Authors:  S Dawood; K Broglio; F J Esteva; N K Ibrahim; S-W Kau; R Islam; K D Aldape; T-K Yu; G N Hortobagyi; A M Gonzalez-Angulo
Journal:  Ann Oncol       Date:  2008-03-11       Impact factor: 32.976

2.  Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development.

Authors:  Anurag Saraf; Christopher S Grubb; Mark E Hwang; Cheng-Hung Tai; Cheng-Chia Wu; Ashish Jani; Matthew E Lapa; Jacquelyn I S Andrews; Sierra Vanderkelen; Steven R Isaacson; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Simon K Cheng; Eileen P Connolly; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-07-03       Impact factor: 4.130

3.  Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

Authors:  S M Swain; J Baselga; D Miles; Y-H Im; C Quah; L F Lee; J Cortés
Journal:  Ann Oncol       Date:  2014-03-31       Impact factor: 32.976
  3 in total
  1 in total

1.  Proteomic Analysis of HCC-1954 and MCF-7 Cell Lines Highlights Crosstalk between αv and β1 Integrins, E-Cadherin and HER-2.

Authors:  Denise de Abreu Pereira; Vanessa Sandim; Thais F B Fernandes; Vitor Hugo Almeida; Murilo Ramos Rocha; Ronaldo J F C do Amaral; Maria Isabel D Rossi; Dário Eluan Kalume; Russolina B Zingali
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.